{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:09:53Z","timestamp":1791266993045,"version":"4.1.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1007\/s11912-023-01411-7","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T10:40:05Z","timestamp":1680691205000},"page":"743-751","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Cardiovascular Effects of Immune Checkpoint Inhibitors: More Than Just Myocarditis"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6331-6908","authenticated-orcid":false,"given":"Alessandro","family":"Inno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Tarantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Parrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Spallarossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Maurea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irma","family":"Bisceglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Silvestris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Gori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,5]]},"reference":[{"issue":"7378","key":"1411_CR1","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature10673","volume":"480","author":"I Mellman","year":"2011","unstructured":"Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480(7378):480\u20139. https:\/\/doi.org\/10.1038\/nature10673.","journal-title":"Nature"},{"issue":"6382","key":"1411_CR2","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350\u20135. https:\/\/doi.org\/10.1126\/science.aar4060.","journal-title":"Science"},{"key":"1411_CR3","doi-asserted-by":"publisher","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012 22;12(4):252\u201364. https:\/\/doi.org\/10.1038\/nrc3239.","DOI":"10.1038\/nrc3239"},{"issue":"26","key":"1411_CR4","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMe1205943","volume":"366","author":"A Ribas","year":"2012","unstructured":"Ribas A. Tumor immunotherapy directed at PD-1. N Engl J Med. 2012;366(26):2517\u20139. https:\/\/doi.org\/10.1056\/NEJMe1205943.","journal-title":"N Engl J Med"},{"issue":"5","key":"1411_CR5","doi-asserted-by":"publisher","first-page":"405","DOI":"10.5301\/tj.5000625","volume":"103","author":"A Inno","year":"2017","unstructured":"\u2022 Inno A, Metro G, Bironzo P, Grimaldi AM, Grego E, Di Nunno V, et al. Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity. Tumori. 2017;103(5):405\u201321. https:\/\/doi.org\/10.5301\/tj.5000625. Comprehensive narrative review on the pathogenesis, clinical entities, and management of immune-related adverse events.","journal-title":"Tumori"},{"issue":"18","key":"1411_CR6","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"\u2022\u2022 Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375(18):1749\u201355. https:\/\/doi.org\/10.1056\/NEJMoa1609214. The first report of fulminant immune-related myocarditis in patients treated with immune checkpoint inhibitors.","journal-title":"N Engl J Med"},{"issue":"10124","key":"1411_CR7","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","volume":"391","author":"JJ Moslehi","year":"2018","unstructured":"Moslehi JJ, Salem JE, Sosman JA, Lebrun-Vignes B, Johnson DB. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018;391(10124):933. https:\/\/doi.org\/10.1016\/S0140-6736(18)30533-6.","journal-title":"Lancet"},{"issue":"9","key":"1411_CR8","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","volume":"19","author":"AR Lyon","year":"2018","unstructured":"\u2022\u2022 Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018;19(9):e447\u201358. https:\/\/doi.org\/10.1016\/S1470-2045(18)30457-1. Comprehensive narrative review on cardiovascular adverse events related to immune checkpoint inhibitors.","journal-title":"Lancet Oncol"},{"issue":"16","key":"1411_CR9","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","volume":"71","author":"SS Mahmood","year":"2018","unstructured":"\u2022\u2022 Mahmood SS, Fradley MG, Cohen JV, Nohria A, Reynolds KL, Heinzerling LM, et al. Myocarditis in patients treated with immune checkpoint inhibitors. J Am Coll Cardiol. 2018;71(16):1755\u201364. https:\/\/doi.org\/10.1016\/j.jacc.2018.02.037. Data from a multi-institutional registry on the presentation and clinical course of 35 cases of immune-related myocarditis.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"1411_CR10","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"\u2022\u2022 Salem JE, Manouchehri A, Moey M, Lebrun-Vignes B, Bastarache L, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19(12):1579\u201389. https:\/\/doi.org\/10.1016\/S1470-2045(18)30608-9. A retrospective study based on data from the pharmacovigilance registry of World Health Organization assessing myocarditis, pericardial disease, and vasculitis associated with immune checkpoint inhibitors.","journal-title":"Lancet Oncol"},{"key":"1411_CR11","doi-asserted-by":"publisher","unstructured":"\u2022 Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal Toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol 2018;4(12):1721-1728. https:\/\/doi.org\/10.1001\/jamaoncol.2018.3923. Erratum in: JAMA Oncol 2018;4(12):1792. Meta-analysis of fatal toxicities related to immune checkpoint inhibitors.","DOI":"10.1001\/jamaoncol.2018.3923"},{"issue":"1","key":"1411_CR12","doi-asserted-by":"publisher","first-page":"e000261","DOI":"10.1136\/jitc-2019-000261","volume":"8","author":"C Dolladille","year":"2020","unstructured":"Dolladille C, Ederhy S, Allouche S, Dupas Q, Gervais R, Madelaine J, et al. Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors. J Immunother Cancer. 2020;8(1):e000261. https:\/\/doi.org\/10.1136\/jitc-2019-000261.","journal-title":"J Immunother Cancer"},{"issue":"8","key":"1411_CR13","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1634\/theoncologist.2018-0130","volume":"23","author":"S Ganatra","year":"2018","unstructured":"Ganatra S, Neilan TG. Immune checkpoint inhibitor-associated myocarditis. Oncologist. 2018;23(8):879\u201386. https:\/\/doi.org\/10.1634\/theoncologist.2018-0130.","journal-title":"Oncologist"},{"key":"1411_CR14","doi-asserted-by":"publisher","first-page":"930797","DOI":"10.3389\/fcvm.2022.930797","volume":"9","author":"V Quagliariello","year":"2022","unstructured":"Quagliariello V, Passariello M, Di Mauro A, Cipullo C, Paccone A, Barbieri A, et al. Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100\/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways. Front Cardiovasc Med. 2022;9:930797. https:\/\/doi.org\/10.3389\/fcvm.2022.930797.","journal-title":"Front Cardiovasc Med"},{"issue":"3","key":"1411_CR15","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1161\/CIRCRESAHA.106.147124","volume":"101","author":"VA Love","year":"2007","unstructured":"Love VA, Grabie N, Duramad P, Stavrakis G, Sharpe A, Lichtman A. CTLA-4 ablation and interleukin-12 driven differentiation synergistically augment cardiac pathogenicity of cytotoxic T lymphocytes. Circ Res. 2007;101(3):248\u201357. https:\/\/doi.org\/10.1161\/CIRCRESAHA.106.147124.","journal-title":"Circ Res"},{"issue":"5502","key":"1411_CR16","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1126\/science.291.5502.319","volume":"291","author":"H Nishimura","year":"2001","unstructured":"Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science. 2001;291(5502):319\u201322. https:\/\/doi.org\/10.1126\/science.291.5502.319.","journal-title":"Science"},{"issue":"12","key":"1411_CR17","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/nm955","volume":"9","author":"T Okazaki","year":"2003","unstructured":"Okazaki T, Tanaka Y, Nishio R, Mitsuiye T, Mizoguchi A, Wang J, et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice. Nat Med. 2003;9(12):1477\u201383. https:\/\/doi.org\/10.1038\/nm955.","journal-title":"Nat Med"},{"key":"1411_CR18","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Hu JR, Florido R, Lipson EJ, Naidoo J, Ardehali R, Tocchetti CG, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors. Cardiovasc Res 2019; 115(5):854-868. https:\/\/doi.org\/10.1093\/cvr\/cvz026. Erratum in: Cardiovasc Res 2019;115(5):868. Comprehensive narrative review on myocarditis, pericardial disease, and vasculitis associated with immune checkpoint inhibitors.","DOI":"10.1093\/cvr\/cvz026"},{"issue":"1","key":"1411_CR19","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s40425-017-0296-4","volume":"5","author":"TG Norwood","year":"2017","unstructured":"Norwood TG, Westbrook BC, Johnson DB, Litovsky SH, Terry NL, McKee SB, et al. Smoldering myocarditis following immune checkpoint blockade. J Immunother Cancer. 2017;5(1):91. https:\/\/doi.org\/10.1186\/s40425-017-0296-4.","journal-title":"J Immunother Cancer"},{"key":"1411_CR20","unstructured":"National Cancer Institute. Common terminology criteria for adverse events (CTCAE) v. 5.0"},{"issue":"29","key":"1411_CR21","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1200\/JCO.22.00369","volume":"40","author":"AR Naqash","year":"2022","unstructured":"Naqash AR, Moey MYY, Cherie Tan XW, Laharwal M, Hill V, Moka N, et al. Major adverse cardiac events with immune checkpoint inhibitors: a pooled analysis of trials sponsored by the national cancer institute-cancer therapy evaluation program. J Clin Oncol. 2022;40(29):3439\u201352. https:\/\/doi.org\/10.1200\/JCO.22.00369.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1411_CR22","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/onco.13931","volume":"26","author":"R Pathak","year":"2021","unstructured":"Pathak R, Katel A, Massarelli E, Villaflor VM, Sun V, Salgia R. Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases. Oncologist. 2021;26(12):1052\u201361. https:\/\/doi.org\/10.1002\/onco.13931.","journal-title":"Oncologist"},{"issue":"8","key":"1411_CR23","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.cjca.2018.03.012","volume":"34","author":"H Mir","year":"2018","unstructured":"\u2022\u2022 Mir H, Alhussein M, Alrashidi S, Alzayer H, Alshatti A, Valettas N, et al. Cardiac complications associated with checkpoint inhibition: a systematic review of the literature in an important emerging area. Can J Cardiol. 2018;34(8):1059\u201368. https:\/\/doi.org\/10.1016\/j.cjca.2018.03.012. A systematic review on cardiovascular toxicity of immune checkpoint inhibitors.","journal-title":"Can J Cardiol"},{"issue":"22","key":"1411_CR24","doi-asserted-by":"publisher","first-page":"00179","DOI":"10.1016\/j.jjcc.2022.07.009","volume":"S0914\u20135087","author":"A Furukawa","year":"2022","unstructured":"\u2022 Furukawa A, Tamura Y, Taniguchi H, Kawamura A, Nagase S, Hayashi A, et al. Prospective screening for myocarditis in cancer patients treated with immune checkpoint inhibitors. J Cardiol. 2022;S0914\u20135087(22):00179\u201384. https:\/\/doi.org\/10.1016\/j.jjcc.2022.07.009. Prospective study on the role of monitoring troponin in patients treated with immune checkpoint inhibitors.","journal-title":"J Cardiol"},{"issue":"25","key":"1411_CR25","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1200\/JCO.18.02464","volume":"37","author":"P Spallarossa","year":"2019","unstructured":"\u2022 Spallarossa P, Tini G, Sarocchi M, Arboscello E, Grossi F, Queirolo P, et al. Identification and management of immune checkpoint inhibitor-related myocarditis: use troponin Wisely. J Clin Oncol. 2019;37(25):2201\u20135. https:\/\/doi.org\/10.1200\/JCO.18.02464. A critical view on the role of monitoring troponin for early detection of immune-related myocarditis.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1411_CR26","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1634\/theoncologist.2017-0452","volume":"23","author":"M Sarocchi","year":"2018","unstructured":"Sarocchi M, Grossi F, Arboscello E, et al. Serial troponin for early detection of nivolumab cardiotoxicity in advanced non-small cell lung cancer patients. Oncologist. 2018;23(8):936\u201342. https:\/\/doi.org\/10.1634\/theoncologist.2017-0452.","journal-title":"Oncologist"},{"key":"1411_CR27","doi-asserted-by":"publisher","unstructured":"\u2022\u2022 Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 2021;39(36):4073-4126. https:\/\/doi.org\/10.1200\/JCO.21.01440. Erratum in: J Clin Oncol 2022 Jan 20;40(3):315. Updated ASCO guidelines on the management of immune-related adverse events.","DOI":"10.1200\/JCO.21.01440"},{"issue":"5","key":"1411_CR28","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jacc.2019.11.049","volume":"75","author":"M Awadalla","year":"2020","unstructured":"Awadalla M, Mahmood SS, Groarke JD, et al. Global longitudinal strain and cardiac events in patients with immune checkpoint inhibitor-related myocarditis. J Am Coll Cardiol. 2020;75(5):467\u201378. https:\/\/doi.org\/10.1016\/j.jacc.2019.11.049.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"1411_CR29","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1002\/ijc.34169","volume":"151","author":"R Cau","year":"2022","unstructured":"Cau R, Solinas C, De Silva P, Lambertini M, Agostinetto E, Scartozzi M, et al. Role of cardiac MRI in the diagnosis of immune checkpoint inhibitor-associated myocarditis. Int J Cancer. 2022;151(11):1860\u201373. https:\/\/doi.org\/10.1002\/ijc.34169.","journal-title":"Int J Cancer"},{"issue":"17","key":"1411_CR30","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.jacc.2009.02.007","volume":"53","author":"MG Friedrich","year":"2009","unstructured":"Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT, et al. Cardiovascular magnetic resonance in myocarditis: a JACC white paper. J Am Coll Cardiol. 2009;53(17):1475\u201387. https:\/\/doi.org\/10.1016\/j.jacc.2009.02.007.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"1411_CR31","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.jacc.2021.01.050","volume":"77","author":"P Thavendiranathan","year":"2021","unstructured":"Thavendiranathan P, Zhang L, Zafar A, Drobni ZD, Mahmood SS, Cabral M, et al. Myocardial T1 and T2 mapping by magnetic resonance in patients with immune checkpoint inhibitor-associated myocarditis. J Am Coll Cardiol. 2021;77(12):1503\u201316. https:\/\/doi.org\/10.1016\/j.jacc.2021.01.050.","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"1411_CR32","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1093\/eurheartj\/ehaa051","volume":"41","author":"L Zhang","year":"2020","unstructured":"Zhang L, Awadalla M, Mahmood SS, Nohria A, Hassan MZO, Thuny F, et al. Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. Eur Heart J. 2020;41(18):1733\u201343. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa051.","journal-title":"Eur Heart J"},{"issue":"3","key":"1411_CR33","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1148\/radiol.2021210814","volume":"301","author":"A Faron","year":"2021","unstructured":"Faron A, Isaak A, Mesropyan N, Reinert M, Schwab K, Sirokay J, et al. Cardiac MRI depicts immune checkpoint inhibitor-induced myocarditis: a prospective study. Radiology. 2021;301(3):602\u20139. https:\/\/doi.org\/10.1148\/radiol.2021210814.","journal-title":"Radiology"},{"issue":"2","key":"1411_CR34","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.acvd.2021.12.001","volume":"115","author":"S Ederhy","year":"2022","unstructured":"Ederhy S, Devos P, Pinna B, Funck-Brentano E, Abbar B, Fenioux C, et al. 18F-fluorodeoxyglucose positron emission tomography\/computed tomography imaging for the diagnosis of immune checkpoint inhibitor-associated myocarditis. Arch Cardiovasc Dis. 2022;115(2):114\u20136. https:\/\/doi.org\/10.1016\/j.acvd.2021.12.001.","journal-title":"Arch Cardiovasc Dis"},{"key":"1411_CR35","doi-asserted-by":"publisher","unstructured":"Porcari A, Baggio C, Fabris E, Merlo M, Bussani R, Perkan A, et al. Endomyocardial biopsy in the clinical context: current indications and challenging scenarios. Heart Fail Rev 2022;1\u201313. https:\/\/doi.org\/10.1007\/s10741-022-10247-5.","DOI":"10.1007\/s10741-022-10247-5"},{"issue":"24","key":"1411_CR36","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1161\/CIRCULATIONAHA.119.044703","volume":"141","author":"L Zhang","year":"2020","unstructured":"\u2022 Zhang L, Zlotoff DA, Awadalla M, Mahmood SS, Nohria A, Hassan MZO, et al. Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis. Circulation. 2020;141(24):2031\u20134. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044703. Retrospective observational study based on an international registry of immune-related myocarditis.","journal-title":"Circulation"},{"issue":"41","key":"1411_CR37","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","volume":"43","author":"AR Lyon","year":"2022","unstructured":"\u2022\u2022 Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43(41):4229\u2013361. https:\/\/doi.org\/10.1093\/eurheartj\/ehac244. Updated guidelines on cardio-oncology of the European Society of Cardiology.","journal-title":"Eur Heart J"},{"issue":"2","key":"1411_CR38","doi-asserted-by":"publisher","first-page":"e001887","DOI":"10.1136\/jitc-2020-001887","volume":"8","author":"J Cautela","year":"2020","unstructured":"Cautela J, Zeriouh S, Gaubert M, Bonello L, Laine M, Peyrol M, et al. Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis. J Immunother Cancer. 2020;8(2):e001887. https:\/\/doi.org\/10.1136\/jitc-2020-001887.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"1411_CR39","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1007\/s00392-020-01648-3","volume":"110","author":"S Peleg Hasson","year":"2021","unstructured":"\u2022 Peleg Hasson S, Salwen B, Sivan A, Shamai S, Geva R, Merimsky O, et al. Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis. Clin Res Cardiol. 2021;110(1):50\u201360. https:\/\/doi.org\/10.1007\/s00392-020-01648-3. Retrospective study on the rechallenge of immune checkpoint inhibitors after immune-related myocarditis.","journal-title":"Clin Res Cardiol"},{"issue":"4","key":"1411_CR40","doi-asserted-by":"publisher","first-page":"e0124059","DOI":"10.1371\/journal.pone.0124059","volume":"10","author":"B Baban","year":"2015","unstructured":"Baban B, Liu JY, Qin X, Weintraub NL, Mozaffari MS. Upregulation of programmed death-1 and its ligand in cardiac injury models: interaction with GADD153. PLoS One. 2015;10(4):e0124059. https:\/\/doi.org\/10.1371\/journal.pone.0124059.","journal-title":"PLoS One"},{"issue":"16","key":"1411_CR41","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.2169\/internalmedicine.4550-20","volume":"59","author":"Y Samejima","year":"2020","unstructured":"Samejima Y, Iuchi A, Kanai T, Noda Y, Nasu S, Tanaka A, et al. Development of severe heart failure in a patient with squamous non-small-cell lung cancer during nivolumab treatment. Intern Med. 2020;59(16):2003\u20138. https:\/\/doi.org\/10.2169\/internalmedicine.4550-20.","journal-title":"Intern Med"},{"issue":"10","key":"1411_CR42","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.jfma.2019.07.025","volume":"119","author":"DY Chen","year":"2020","unstructured":"Chen DY, Huang WK, Chien-Chia WuV, Chang WC, Chen JS, Chuang CK, et al. Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: a review when cardiology meets immuno-oncology. J Formos Med Assoc. 2020;119(10):1461\u201375. https:\/\/doi.org\/10.1016\/j.jfma.2019.07.025.","journal-title":"J Formos Med Assoc"},{"issue":"21","key":"1411_CR43","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.117.030571","volume":"136","author":"M Escudier","year":"2017","unstructured":"Escudier M, Cautela J, Malissen N, Ancedy Y, Orabona M, Pinto J, et al. Clinical features, management, and outcomes of immune checkpoint inhibitor-related cardiotoxicity. Circulation. 2017;136(21):2085\u20137. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.030571.","journal-title":"Circulation"},{"issue":"2","key":"1411_CR44","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jaccas.2019.11.080","volume":"2","author":"J Chahine","year":"2020","unstructured":"Chahine J, Collier P, Maroo A, Tang WHW, Klein AL. Myocardial and pericardial toxicity associated with immune checkpoint inhibitors in cancer patients. JACC Case Rep. 2020;2(2):191\u20139. https:\/\/doi.org\/10.1016\/j.jaccas.2019.11.080.","journal-title":"JACC Case Rep"},{"issue":"7","key":"1411_CR45","doi-asserted-by":"publisher","first-page":"3178","DOI":"10.1007\/s12325-020-01386-y","volume":"37","author":"ML Canale","year":"2020","unstructured":"Canale ML, Camerini A, Casolo G, Lilli A, Bisceglia I, Parrini I, et al. Incidence of pericardial effusion in patients with advanced non-small cell lung cancer receiving immunotherapy. Adv Ther. 2020;37(7):3178\u201384. https:\/\/doi.org\/10.1007\/s12325-020-01386-y.","journal-title":"Adv Ther"},{"issue":"1","key":"1411_CR46","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s40425-019-0760-4","volume":"7","author":"A Saade","year":"2019","unstructured":"Saade A, Mansuet-Lupo A, Arrondeau J, Thibault C, Mirabel M, Goldwasser F, et al. Pericardial effusion under nivolumab: case-reports and review of the literature. J Immunother Cancer. 2019;7(1):266. https:\/\/doi.org\/10.1186\/s40425-019-0760-4. Erratum in: J Immunother Cancer 2019;7(1):335.","journal-title":"J Immunother Cancer"},{"issue":"10","key":"1411_CR47","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1007\/s00262-021-02938-z","volume":"70","author":"A Inno","year":"2021","unstructured":"\u2022\u2022 Inno A, Maurea N, Metro G, Carbone A, Russo A, Gori S. Immune checkpoint inhibitors-associated pericardial disease: a systematic review of case reports. Cancer Immunol Immunother. 2021;70(10):3041\u201353. https:\/\/doi.org\/10.1007\/s00262-021-02938-z. Systematic review of case reports and series of pericardial disease associated with immune checkpoint inhibitors.","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"1411_CR48","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s11926-019-0828-7","volume":"21","author":"TM Crout","year":"2019","unstructured":"\u2022\u2022 Crout TM, Lennep DS, Kishore S, Majithia V. Systemic Vasculitis associated with immune check point inhibition: analysis and review. Curr Rheumatol Rep. 2019;21(6):28. https:\/\/doi.org\/10.1007\/s11926-019-0828-7. Systematic review of cases of vasculitis associated with immune checkpoint inhibitors.","journal-title":"Curr Rheumatol Rep"},{"issue":"9","key":"1411_CR49","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1007\/s10067-018-4177-0","volume":"37","author":"A Daxini","year":"2018","unstructured":"Daxini A, Cronin K, Sreih AG. Vasculitis associated with immune checkpoint inhibitors-a systematic review. Clin Rheumatol. 2018;37(9):2579\u201384. https:\/\/doi.org\/10.1007\/s10067-018-4177-0.","journal-title":"Clin Rheumatol"},{"issue":"2","key":"1411_CR50","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00431-009-1002-4","volume":"169","author":"JK Chun","year":"2010","unstructured":"Chun JK, Kang DW, Yoo BW, Shin JS, Kim DS. Programmed death-1 (PD-1) gene polymorphisms lodged in the genetic predispositions of Kawasaki Disease. Eur J Pediatr. 2010;169(2):181\u20135. https:\/\/doi.org\/10.1007\/s00431-009-1002-4.","journal-title":"Eur J Pediatr"},{"issue":"5","key":"1411_CR51","first-page":"950","volume":"29","author":"R Giscombe","year":"2002","unstructured":"Giscombe R, Wang X, Huang D, Lefvert AK. Coding sequence 1 and promoter single nucleotide polymorphisms in the CTLA-4 gene in Wegener\u2019s granulomatosis. J Rheumatol. 2002;29(5):950\u20133.","journal-title":"J Rheumatol"},{"issue":"24","key":"1411_CR52","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","volume":"142","author":"ZD Drobni","year":"2020","unstructured":"\u2022\u2022 Drobni ZD, Alvi RM, Taron J, Zafar A, Murphy SP, Rambarat PK, et al. Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque. Circulation. 2020;142(24):2299\u2013311. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.049981. Large matched cohort study assessing the association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque.","journal-title":"Circulation"},{"key":"1411_CR53","doi-asserted-by":"publisher","first-page":"652186","DOI":"10.3389\/fcvm.2021.652186","volume":"8","author":"A Inno","year":"2021","unstructured":"\u2022 Inno A, Chiampan A, Lanzoni L, Verz\u00e8 M, Molon G, Gori S. Immune checkpoint inhibitors and atherosclerotic vascular events in cancer patients. Front Cardiovasc Med. 2021;8:652186. https:\/\/doi.org\/10.3389\/fcvm.2021.652186. Comprehensive narrative review on preclinical and clinical evidence of the association between immune checkpoint inhibitors with atherosclerosis.","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"1411_CR54","doi-asserted-by":"publisher","first-page":"e001361","DOI":"10.1136\/jitc-2020-001361","volume":"8","author":"A Cortellini","year":"2020","unstructured":"Cortellini A, Tucci M, Adamo V, Stucci LS, Russo A, Tanda ET, et al. Integrated analysis of concomitant medications and oncological outcomes from PD-1\/PD-L1 checkpoint inhibitors in clinical practice. J Immunother Cancer. 2020;8(2):e001361. https:\/\/doi.org\/10.1136\/jitc-2020-001361.","journal-title":"J Immunother Cancer"},{"issue":"14","key":"1411_CR55","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","volume":"42","author":"JP Collet","year":"2021","unstructured":"Collet JP, Thiele H, Barbato E, Barth\u00e9l\u00e9my O, Bauersachs J, Bhatt DL, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289\u2013367. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa575. (Erratum.In:EurHeartJ2021;42(19):1908.Erratumin:EurHeartJ2021;42(19):1925.Erratumin:EurHeartJ2021May13).","journal-title":"Eur Heart J"},{"issue":"2","key":"1411_CR56","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"B Ibanez","year":"2017","unstructured":"Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2017;39(2):119\u201377. https:\/\/doi.org\/10.1093\/eurheartj\/ehx393.","journal-title":"Eur Heart J"},{"issue":"29","key":"1411_CR57","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.1200\/JCO.21.01808","volume":"40","author":"D Laenens","year":"2022","unstructured":"Laenens D, Yu Y, Santens B, Jacobs J, Beuselinck B, Bechter O, et al. Incidence of cardiovascular events in patients treated with immune checkpoint inhibitors. J Clin Oncol. 2022;40(29):3430\u20138. https:\/\/doi.org\/10.1200\/JCO.21.01808.","journal-title":"J Clin Oncol"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-023-01411-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-023-01411-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-023-01411-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T05:13:07Z","timestamp":1686287587000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-023-01411-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,5]]},"references-count":57,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["1411"],"URL":"https:\/\/doi.org\/10.1007\/s11912-023-01411-7","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,5]]},"assertion":[{"value":"21 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}